Popular

Tony Kiuru (UPM Biomedicals)
Expert interviews
HealthIn vitro

Tony Kiuru (UPM Biomedicals)

Tony Kiuru discusses GrowDex, which is an animal free, ready to use hydrogel that mimics the extracellular matrix (ECM) and supports cell growth and differentiation with consistent results. Bridging the gap between in vitro and in vivo studies GrowDex can be used for 3D cell culture for spheroid and /organoids, in personalised medicine, regenerative medicine, organ-on-a-chip models, drug release studies, 3D printing and much more. GrowDex hydrogel is manufactured according to ISO13485. You can find more information about GrowDex at https://www.upmbiomedicals.com/siteassets/documents/growdex-brochure-2018.pdf and https://www.linkedin.com/company/growdex/ . General email address: biomedicals@upm.com.
01:113 years ago
Zebrafish in toxicity testing
Innovation examples

Zebrafish in toxicity testing

Zebrafish are increasingly recognised as a useful model for toxicity testing of chemical substances. Testing strategies are becoming more based on mechanisms of toxicity structured in adverse outcome pathways describing the chain of events leading to toxicity or disease. Using a battery of dedicated in vitro and in silico assays, insight can be gained in how exposure leads to disease. For certain diseases it is known that toxicity relies on the interaction between different organs and cell types, which requires research on whole organisms in addition to simple in vitro models. The zebrafish is considered a valuable whole organism model in a mechanism-based testing strategy. At RIVM, the zebrafish embryo model is used for testing the effect of chemical substances on several adverse outcomes and diseases. For more information see: https://ehp.niehs.nih.gov/doi/10.1289/EHP9888; https://doi.org/10.3390/ijerph18136717; www.linkedin.com/in/harm-heusinkveld
03:017 months ago
The Beyond Animal Testing Index
Projects and initiatives

The Beyond Animal Testing Index

The Beyond Animal Testing Index (BATI) was designed after the Access to Medicine Index with the aim to be a transparent, objective and independent benchmark that provide public research organisations and their stakeholders insight in what efforts and contributions they make in the transition to animal free innovation and to provide organisations incentive to learn from and inspire each other with regard to the implementation of research practices without the use of animals for the benefit of science.
02:004 months ago
Avatar Zoo - teaching animal anatomy using virtual reality
Innovation examples
EducationInnovation

Avatar Zoo - teaching animal anatomy using virtual reality

Animals are essential to train the next generation of scientists understand diseases and develop treatments for humans as well as animals. Therefore, animals are used for educational purposes. Technologies such as Virtual Reality and Augmented Reality can be employed to reduce the number of animals in the future. Prof. Dr. Daniela Salvatori is working on the development of 'Avatar Zoo' together with UMCU and IT. Live animals are replaced by holographic 3D in this flexible platform. With these holograms one is able to study the anatomical, physiological and pathological systems and processes of all kinds of animals. Avatar Zoo won the Venture Challenge 2021 for the development of virtual reality models that can be used for anatomy classes and practical training.
02:4019 months ago
Respiratory toxicity using in vitro methods
Innovation examples

Respiratory toxicity using in vitro methods

The airways form a barrier for inhaled compounds, however, such compounds may cause local effects in the airways or may lead to lung diseases, such as fibrosis or COPD. Cell models of the respiratory tract, cultured at the air-liquid-interface (ALI) are a relevant model to assess the effects of inhaled compounds on the airways. Such models allow human relevant exposure, which is via the air, and assessment of effects on the epithelial cell layer. At RIVM we use air-liquid-interface cultured cell models and expose these to airborne compounds to assess the effects of agents such as nanomaterials, air pollutants or compounds from cigarette smoke. By using a mechanism-based approach to assess the effects of these compounds we invest in animal-free alternatives that better predict adverse effects in humans.
02:2414 months ago
Charlotte Blattner (Harvard Law School)
Expert interviews
Policy

Charlotte Blattner (Harvard Law School)

Charlotte Blattner (Harvard Law School, Animal Law & Policy Program)
01:063 years ago
Kirsten Baken (VITO)
Expert interviews
HealthToxicology

Kirsten Baken (VITO)

Kirsten Baken (VITO, www.vito.be) discusses biomonitoring as part of the HBM4EU project (www.hbm4eu.eu). An example of the use of human biomarkers can be found at https://www.sciencedirect.com/science/article/pii/S0013935119302658 .
01:273 years ago
Optimizing CAR-T-cell therapy using 3D tumor models and real-time cell imaging
Conferences abstracts

Optimizing CAR-T-cell therapy using 3D tumor models and real-time cell imaging

Chimeric antigen receptor (CAR) T-cell therapy accounts for one of the most promising therapeutic advances in cancer immunotherapy. In this form of adoptive cell transfer, T-cells of a patient are engineered to express so-called ‘CARs’, in which the antigen-recognition capacity of antibodies is combined with T-cell activating domains. So far, CAR-T-cell therapy obtained its most impressive results in hematological malignancies resulting in the approval of five CAR-T cell products by the FDA for hematologic indications. However, CAR-T-cell therapy has not mirrored its success in solid tumors. The poor efficacy of CAR-T-cell therapy in solid tumors has, in part, been attributed to the lack of understanding in how CAR-T-cells function in a solid tumor microenvironment. Classical validation methods rely on the use of specificity and functionality assays in 2D models against adherent target cells or target cells in suspension. Yet, by using these models, observations made in vitro may differ greatly to an in vivo situation where tumors are engrafted in 3D structures. We developed a more relevant and translational 3D tumor model using eGFP+ target cells. This allows us to couple 3D tumor cell killing by CAR-T-cells to live-cell imaging, providing an efficient quantification of target cell death. As proof- of-concept, we used a 3D model of eGFP+ glioblastoma cells and CAR-T-cells targeting a pan-cancer antigen. This 3D glioblastoma model allowed us to show that classical scFv-based CAR-T-cell therapy of glioblastoma cells can be improved by nanoCAR-T-cells. Furthermore, combining nanoCAR-T-cell therapy with a genetic approach of nanobody-based anti-PD-L1 immune checkpoint blockade further increased the cytotoxicity of the nanoCAR-T-cell therapy.
03:2512 months ago
Tumor-on-chips to study delivery of protein therapeutics
Innovation examples
HealthInnovationIn vitro

Tumor-on-chips to study delivery of protein therapeutics

Valentina is a PhD candidate at the Department of Biochemistry at Radboudumc. Her research focuses on developing and applying organ-on-chip technologies, such as tumor-on-a-chip systems, to study the tissue-specific and cytosolic delivery of protein therapeutics. Valentina's research has also aimed at bridging the gap between engineers and biologists, promoting the use of microfluidic organ-on-chip technologies to answer more relevant biological questions. One example of this is the development of a mathematical model that could be applied to study drug delivery and diffusion in a tumor-on-a-chip system and to extrapolate possible outcomes of the delivery of therapeutic proteins to tumors in the human body. Another collaboration led to the development of a tumor-on-a-chip where hypoxic conditions can be replicated and investigated, and where the targeting of specific hypoxia markers in tumor cells can be investigated.
00:473 months ago
Erwin Roggen (ToxGenSolutions)
Expert interviews
ToxicologyIn vitro

Erwin Roggen (ToxGenSolutions)

ToxGenSolutions provides a cutting-edge patchwork of test methods required for modern testing and assessment of compounds and products. It builds on a virtual generic platform of leading test and technology developers providing novel technologies addressing key events in outcome pathways. ToxGenSolutions products are proprietary mechanism-based gene signatures for identification and classification of toxicants during screening, product development and safety assessment. More information on https://toxgensolutions.eu/ .
01:073 years ago
Whole blood assessment of thrombosis tendency
Innovation examples
HealthInnovation

Whole blood assessment of thrombosis tendency

Transgenic animals are often subjected to short and long term experimental models of thrombosis and atherosclerosis with considerable discomfort to the animal. This project aims to: 1) replace (human blood instead of animal blood), 2) reduce (a few drops of blood per test), and 3) refine (replace in vivo by in vitro testing with isolated blood) the use of laboratory animals with two new small blood volume function tests—the perfusion chamber and the thrombin generation test. Both tests will be equipped with a simple detection capability, which is affordable for laboratories. Their application is not only in the field of thrombosis and haemostasis but also for the investigation of other blood-related diseases, such as arteriosclerosis, diabetes and cancer. By Sanne Brouns (Department of Biochemistry CARIM, Maastricht University, the Netherlands) and Linda Herfs (Flowchamber B.V.).
01:202 years ago
Daniela Salvatori: TPI Utrecht
Expert interviews
HealthEducation

Daniela Salvatori: TPI Utrecht

Prof. dr. Daniela Salvatori, chair of TPI Utrecht, presents the aims of the local TPI group and invites all who want to share their ideas or questions on the transition towards animal-free innovations to get in touch via uu.nl/tpi.
02:232 years ago